FIELD: medicine; oncology; immunotherapy.
SUBSTANCE: group of inventions relates to the field of medicine, namely to oncology and immunotherapy; it is intended for inhibition of tumor growth in an individual. A pharmaceutical composition or combination containing human arginase I enzyme containing cobalt cofactor, and an immune-oncological agent is used in a method for the inhibition of tumor growth in an individual. The immune-oncological agent is selected from a group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-OX40 antibody and an anti-OX40L antibody. Therapeutic amount of human arginase I enzyme containing cobalt cofactor is from 0.1 mg/kg to 5 mg/kg. A combination is also used for the treatment of malignant tumor in a patient, including a pharmaceutical composition containing pegylated human arginase I enzyme containing cobalt cofactor, and a therapeutic agent modulating the immune system, containing a pharmaceutical composition containing an immune-oncological agent selected from an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-OX40 antibody or an anti-OX40L antibody.
EFFECT: use of the group of inventions allows for increasing the efficiency of inhibition of tumor growth in a subject due to an additive and synergetic antitumor effect of combination therapy.
14 cl, 7 dwg, 3 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PREPARING AND USING MONO- AND DI-PEGYLATED IL-10 | 2009 |
|
RU2549702C2 |
| PRODUCING PEGYLATED FRAGMENTS OF GD2-SPECIFIC ANTIBODIES INDUCING DIRECT CELL DEATH OF GD2-POSITIVE TUMOR CELLS, AND USE THEREOF IN THERAPY OF GD2-POSITIVE TUMORS | 2017 |
|
RU2663104C1 |
| METHODS OF USING INTERLEUKIN-10 FOR TREATING DISEASES AND DISORDERS | 2014 |
|
RU2679889C2 |
| SPARC-BINDING PEPTIDES AND USING THEM | 2009 |
|
RU2491085C2 |
| CREATION OF CONJUGATES OF GD2-SPECIFIC ANTIBODIES AND FRAGMENTS OF GD2-SPECIFIC ANTIBODIES WITH PREPARATIONS | 2019 |
|
RU2733430C1 |
| THERAPY OF METASTATIC UROTHELIAL CANCER USING ANTIBODY-DRUG CONJUGATE SATSITUZUMAB GOVITECAN (IMMU-132) | 2017 |
|
RU2757395C2 |
| MODULATION OF TUMOR RESISTANCE BY PROTEIN-MEDIATED O DELIVERY | 2016 |
|
RU2731450C2 |
| METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF KIDNEY CANCER | 2017 |
|
RU2752322C2 |
| ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 | 2018 |
|
RU2812915C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
